Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
Medications and Charcot-Marie-Tooth Disease
There currently are no available treatments that act to slow the progression of Charcot-Marie-Tooth disease. There are promising CMT research studies that indicate that this may change in the near…
CMTA Awards $225,483 for Study On Using ASOs to Treat CMT2E
…is the largest philanthropic funder of CMT research worldwide. The CMTA’s Strategy to Accelerate Research (STAR) brings the best CMT researchers, clinicians, and experts in therapy development together with patients,…
CMTA Announces Participation in Seed Extension Round for Armatus Bio for Novel CMT1A Gene Therapy
…went on to say that “the venture philanthropy arm will work in tandem with STAR (Strategy to Accelerate Research), the arm of CMTA which is the largest private funder of…
Understanding CMT4J: A Natural History Study
The purpose of this study is to observe and understand the progression of CMT4J over time. By tracking the natural course of the disease, researchers aim to discover how CMT4J…
Sign Up for CMTA eNews
Thank you for your interest in signing up for CMTA E-News. We look forward to keeping you informed about CMTA research, events, fundraising and more! By submitting this form, you…
Evolution: CMTA Board Welcomes Coulie & Marks
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments and a cure to patients, is pleased to announce the appointment of Bernard…
Summer 2024 CMTA Report: A Season of Renewal and Progress
…intelligence revolutionizes CMT diagnosis, treatment, and management with a dedicated feature by CMTA Chief Research Officer Katherine Forsey, PhD, on page 20 in her column, Under the Microscope. Additionally, community…
The CMT&ME Study: What It’s Like to Live with CMT
There’s been little research to date into how CMT affects the lives of patients. The French company Pharnext, CMT scientific experts, and international patient advocacy organizations (PAOs) have therefore partnered…
Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease
…and Chief Executive Officer of Acceleron. “We wish to thank all of the patients, families, caregivers, and investigators for their support and participation in this research. I also want to…
Karen Brown, CMTAthlete
…real-life community of support and accountability, I created a Circle of Friends on the CMTA website and asked my friends and family to give to CMT research in support of…